| |
| |
|
| |
|
|
|
| |
Content for site developed under the guidance of the TRACK Advisory Council.
|
|
 |
|
| |
 |
|
|
|
| |
_Antithrombotic Therapy in the Management of Acute Coronary Syndromes |
| |
|
| |
|
|
This CME activity has expired. CME credit is no longer available for this activity. However, the content will remain posted for your viewing convenience. |
HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW SITE
The programs requires version 5.5 browsers or higher from Microsoft or Netscape or Firefox 1.0. Certain activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
|
ACCREDITATION STATEMENT |
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Elsevier Office of Continuing Medical Education (EOCME) and Excerpta Medica, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians. |
|
FACULTY DISCLOSURES
|
|
The EOCME has implemented a process where everyone who is in a position to control the content of an educational activity must disclose the existence of any significant financial interest or any other relationship they or their spouse may have with the manufacturer(s) of any commercial product discussed during the activity.
Those involved with the development, presentation, and distribution of the content of this CME activity disclose the following:
| Faculty Member |
|
Manufacturer |
|
Relationship |
| Deepak L. Bhatt, MD |
|
Bristol-Myers Squibb Company, The sanofi-aventis Group |
|
Grants/Research Support Consultant Grants/Research Support |
| Geno J. Merli, MD |
|
AstraZeneca, The sanofi-aventis Group |
|
Grants/Research Support, Consultant, Speaker’s Bureau |
| Geno J. Merli, MD |
|
Bacchus Vascular, Inc. |
|
Consultant |
| Geno J. Merli, MD |
|
Bayer Pharmaceuticals Corporation |
|
Grants/Research Support |
| Mark J. Flanick, MS |
|
Nothing to Disclose |
|
Nothing to Disclose | |
|
INFORMATION ON CME CREDIT |
|
The EOCME designates this educational activity for a maximum of 1.5 category 1 credits toward the American Medical Association (AMA) Physician’s Recognition Award (PRA). Each physician should claim only those hours of credit that he/she actually spent in the educational activity. |
|
FINANCIAL SUPPORT |
|
This CME activity is jointly sponsored by the EOCME and Excerpta Medica and supported by an unrestricted educational grant from sanofi-aventis U.S. |
|
INTENDED AUDIENCE |
|
This activity is intended for cardiologists, interventional cardiologists, and other critical-care specialists who treat patients with acute coronary events. |
|
GOAL OF THE ACTIVITY |
|
This activity will help participants interpret and implement the latest guidelines on the use of antithrombotic drugs in patients with acute coronary syndromes (ACS). The participants will be able to describe the current American College of Cardiology/American Heart Association (ACC/AHA) treatment algorithms and recent trial data that may impact treatment approaches for ACS. |
|
EDUCATIONAL OBJECTIVES |
|
Upon completion of this activity, participants will be able to:
- List the cornerstones of treatment and the recommended use of antithrombotic therapies for unstable angina/non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI)
- Implement the treatment recommendations from the ACC/AHA guidelines for UA-NSTEMI/STEMI
- List the advantages and disadvantages of various therapeutic options that have been used to manage acute coronary events
- Place the guidelines into context based on recent trial data for bivalirudin, clopidogrel, and enoxaparin
|
|
CONTENT DEVELOPMENT COMMITTEE |
|
Deepak L. Bhatt, MD
Geno J. Merli, MD
Mark J. Flanick, MS |
|
UNAPPROVED USE DISCLOSURE |
|
The EOCME requires CME faculty (speakers) to disclose to the attendees:
1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and
2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information
|
|
CME PARTICIPANT DEMOGRAPHICS |
|
Antithrombotic Therapy in the Management of Acute Coronary Syndromes
Release date: May 10, 2005
Expiration date: May 10, 2007
Estimated time to complete activity: 1.5 hours |
|
The following slide presentation provides a basic overview of current treatment recommendations for cardiologists, interventional cardiologists, and other critical care specialists who treat patients with acute coronary events, including interpretation and implementation of the latest guidelines on the use of antithrombotic drugs in patients with acute coronary syndromes (ACS). The current American College of Cardiology/American Heart Association (ACC/AHA) treatment algorithms for ACS are described as well as recent trial data that may impact on those treatment algorithms.
|
|
| |
|
|
| |
|
|